Skip to content

G&A at other companies

CareDx logo
CareDxCDNA
$30.48M+33.9%
Guardant Health logo
Guardant HealthGH
$57.93M+23.4%
Fulgent Genetics, Inc. logo
Fulgent Genetics, Inc.FLGT
$27.68M+9.5%
Veracyte logo
VeracyteVCYT
$23.68M-30.0%

Other financials

Income statement

See full
Revenue$32.0K-98.5%
Gross profit$15.0K-98.9%
Operating income-$4.4M+35.1%
Net income-$4.3M+35.7%
EPS (diluted)-$0.12+53.8%

Balance sheet

See full
Cash & equivalents$28.2M-9.1%
Total debt$2.9M-13.5%
Total equity-$10.7M-205%
Total assets$40.4M-33.0%

Cash flow

See full
Operating cash flow-$7.6M-30.8%
CapEx$613.0K+99.7%
Free cash flow-$8.3M-34.3%

Valuation

See full
Market cap$185.35M+92.3%
Enterprise value$160.03M+113%
P/S95.1×+72.5×

Profitability

See full
Gross margin51.3%-3.0pp
Operating margin-2,500.7%+4,459pp
Net margin-2,454.6%+4,017pp
FCF margin-1,409.7%-6,023pp

Returns & leverage

See full
Return on equity-532.9%-717pp
Debt / equity2.9×+2.8×
Current ratio2.5×-1.2×

Where this comes from

Reported directly by IMDX in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: IMDX’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about IMDX's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is IMDX's G&A?
IMDX (IMDX) reported G&A of $2.99M in Q1 2026.
How has IMDX's G&A changed year-over-year?
IMDX's G&A decreased by 4.0% year-over-year, from $3.12M to $2.99M.
What is the long-term trend for IMDX's G&A?
Over 4 years (2021 to 2025), IMDX's G&A has grown at a -16.9% compound annual growth rate (CAGR), from $22.34M to $10.63M.
What does G&A mean?
Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.